You are here: Industry Insights > Market News > US FDA completes inspection of Lupin’s Nagpur plant

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Retatrutide 2381089-83-2

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

US FDA completes inspection of Lupin’s Nagpur plant

financialexpressMay 21, 2018

Tag: US , FDA , Lupin’s Nagpur plant

Favorites

Lupin said the US health regulator has completed inspection of its Nagpur facility without making any observations.

In a BSE filing, Lupin "announced successful completion of an inspection carried out by the United States Food and Drug Administration (US FDA) at its Nagpur facility. The inspection concluded without any observations".

Lupin said its Nagpur facility manufactures oral solid products.

Register as Visitor to CPhI China 2018!

Previous:IPGA felicitates Dilip Sanghvi, MD, Sun Pharma

Next:9-valent HPV Vaccine will Go through Customs at RMB 1,298/Piece and be Marketed Next Month!

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

PRNewswireDecember 18, 2024

Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

US FDA completes inspection of Lupin’s Nagpur plant | Pharmasources.com

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

US FDA completes inspection of Lupin’s Nagpur plant

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

You may like
More>>

US FDA completes inspection of Lupin’s Nagpur plant

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

You may likeMore>>

You may like
More>>